Non-Investigational Antibody-Drug Conjugates (ADC)
Pre-clinicalRecruiting 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
HER2-negative Breast Cancer
Conditions
HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, Metastatic Breast Cancer, HR+ HER2 Breast Cancer, Metastatic Triple Negative Breast Cancers, Metastatic Triple-Negative Breast Carcinoma
Trial Timeline
Oct 8, 2025 → Dec 31, 2030
NCT ID
NCT06774027About Non-Investigational Antibody-Drug Conjugates (ADC)
Non-Investigational Antibody-Drug Conjugates (ADC) is a pre-clinical stage product being developed by Gilead Sciences for HER2-negative Breast Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06774027. Target conditions include HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, Metastatic Breast Cancer.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06774027 | Pre-clinical | Recruiting |
Competing Products
19 competing products in HER2-negative Breast Cancer